ArticlePloS one2025
Exploring the antimicrobial and antibiofilm potency of four essential oils against selected human pathogens using in vitro and in silico approaches.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Neglected ESKAPE Pathogens in Companion Animals: Diagnostic Bias, Zoonotic Blind Spots, and Phytotherapeutic Opportunities.Pathogens (Basel, Switzerland) · 2026Review
- In Vitro and In Silico Evaluation of the Anti-Infective Potential of EF24-Analogous Curcuminoids: Antiprotozoal Activity and HIV-1 Ribonuclease H Inhibition.Pathogens (Basel, Switzerland) · 2026Article
- In Vitro and In Silico Investigations of Antifungal Activity of Ethyl Acetate Extracts of Various Species of Swertia Against Aspergillus fumigatus.Chemistry & biodiversity · 2026Article
- Clinical Potential of Essential Oils: Cytotoxicity, Selectivity Index and Antimicrobial Activity Against Gram-Negative ESKAPEE Pathogens.Antibiotics (Basel, Switzerland) · 2026Review
- The Effect of Variations in Temperature and Contact Time of Zingerone, [6]-Gingerol and Shogaol as Disinfectants onMicroorganisms · 2026Article
- Article
- Preliminary Assessment ofGenes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multi-drug-resistant (MDR) pathogens pose a significant global health challenge, underscoring the urgent need for novel antimicrobial agents with minimal toxicity to humans. This study investigated the in vitro and in silico antimicrobial and antibiofilm potentials of four essential oils (EOs): clove bud oil (CBO; Syzygium aromaticum L.), black seed oil (BSO; Nigella sativa L.), cinnamon bark oil (CNBO; Cinnamomum zeylanicum), and citronella oil (CTLO; Cymbopogon nardus L.), against 19 selected human pathogens, including MDR strains. Among the tested EOs, CBO, BSO, and CNBO exhibited the highest antibacterial activity against Staphylococcus epidermidis, with the mean zone of inhibition diameters (ZIDs) of 20.0 ± 0.2 mm, 46.0 ± 0.3 mm, and 32.0 ± 0.1 mm, respectively, at a concentration of 10 µL/disc, while CTLO displayed no antibacterial activity. CNBO demonstrated superior antifungal activity, with the mean ZIDs of 49.0 ± 0.3 mm and 36.0 ± 0.3 mm for Candida albicans and Aspergillus niger, respectively. Molecular docking analyses revealed robust interactions of key bioactive compounds-eugenol (EU) from CBO, thymoquinone (TQ) from BSO, cinnamaldehyde (CN) from CNBO, citronellal (CIT) and linalool (LIN) from CTLO-with microbial target proteins, substantiating their antimicrobial and antibiofilm potential. Notably, CTLO, despite limited in vitro activity, exhibited unique binding interactions in silico, suggesting potential niche applications. These findings underscore the translational potential of EOs as alternative antimicrobial therapies against MDR infections, particularly biofilm-associated infections, and highlight the need for further in vivo studies to validate their efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.